LLY vs OM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Outset Medical exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. Despite a strong current ratio of 6.67 suggesting short-term liquidity, the company suffers from catastrophic long-term price erosion (-99.5% over 5 years) and negative revenue growth. The combination of deep negative profit margins (-68.34%) and consistent insider selling suggests a lack of confidence in a turnaround. While analysts maintain a 'buy' rating with a $9.00 target, the deterministic data points to a high risk of further capital impairment.
Compare Another Pair
Related Comparisons
LLY vs OM: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Outset Medical, Inc. (OM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.